Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-CEL UVEC Cell Therapy for Chronic Anal Fissure
NCT06456073Phase 1Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in chronic anal fissure (CAF), sponsored by Weill Cornell Medicine. Primary endpoints: Number of severe injection site reactions up to 180 days, Number of severe injection site reactions that are serious adverse events related to IP up to 180 days and 1 more. Started Sep 2024; status: recruiting.
02
Conditions
chronic anal fissure (CAF)
Beyond the preview
Go deeper on NCT06456073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456073.